Speaker: Hui Zhang, Johns Hopkins University
Topic: Glycoproteomics: methods and applications in clinical proteomics
Date: May 20, 2024
Time: 6:15 pm Dinner, 7:15 pm Presentation
Location: Shimadzu Scientific Instrument, Inc. Training Center 7100 Riverwood Drive, Columbia, MD 21046 (Directions)
Dinner: Please RSVP to Jonathan Ferguson (jonathan.ferguson33@gmail.com) by Friday, May 17 if you will be attending the dinner.
Abstract: The integration of proteomic technologies into clinical practice indeed holds significant promise for revolutionizing disease diagnosis, prognosis, and treatment. By delving into the intricate world of proteins and their modifications, particularly protein glycosylation, researchers aim to unravel the complexities underlying various diseases.
Glycoproteomics, a specialized field within proteomics and glycomics, focuses on the comprehensive characterization of glycoproteins. In recent years, mass spectrometry-based technologies have emerged as the cornerstone of advancements in glycoproteomics. One of the main challenges in glycoproteomics lies in the heterogeneity of glycosylation of glycoproteins, including variations in glycan types, sites of glycosylation, and the specific glycans attached to each glycosylation site. To overcome these challenges, we have developed various methodologies in glycoprotein glycopeptide enrichment, liquid chromatography, mass spectrometry, and software tools, for precise site-specific glycan assignments.
The developed glycoproteomic techniques offer unprecedented opportunities to investigate the interplay between genomic, environmental factors, and protein modifications. By employing these advanced technologies to investigate tumors, we have gained invaluable insights into cancer biology, particularly pertaining to protein modifications such as glycosylation.
In summary, the integration of glycoproteomic approaches into biomedical research has the potential to significantly advance our understanding of cancer and pave the way for more personalized and effective clinical interventions.
—————-
lightning talk
Ying Hao, Ph.D. (NIH/NIA/IRP)